This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Why You Should Add Encompass Health (EHC) to Your Portfolio Now
by Zacks Equity Research
Encompass Health (EHC) remains well-poised for growth on the back of robust demand for effective inpatient rehabilitation services, joint ventures and solid cash reserves.
Nexstar Media and ASGN have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Nexstar Media and ASGN have been highlighted as Zacks Bull and Bear of the Day.
Is Stagflation Round the Corner? 3 Ultra-Safe Picks
by Tirthankar Chakraborty
Since it's becoming difficult to downplay the idea of stagflation, investors should place their bets on ultra-safe stocks such as Western Union (WU), Frontline (FRO) and Organon (OGN).
Surging Earnings Estimates Signal Upside for Organon (OGN) Stock
by Zacks Equity Research
Organon (OGN) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Best Value Stocks to Buy for May 13th
by Zacks Equity Research
OGN, ODP and ASC made it to the Zacks Rank #1 (Strong Buy) value stocks list on May 13, 2024.
What Makes Organon (OGN) a New Buy Stock
by Zacks Equity Research
Organon (OGN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Organon (OGN) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Organon (OGN) delivered earnings and revenue surprises of 25.77% and 3.44%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Organon (OGN) Gears Up to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
Organon's (OGN) first-quarter results are likely to reflect growth in its biosimilars and established brand franchises with lighter fertility product sales amid foreign exchange headwinds.
Earnings Preview: Surgery Partners (SGRY) Q1 Earnings Expected to Decline
by Zacks Equity Research
Surgery Partners (SGRY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Stay Ahead of the Game With Organon (OGN) Q1 Earnings: Wall Street's Insights on Key Metrics
by Zacks Equity Research
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Organon (OGN), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended March 2024.
Earnings Preview: Organon (OGN) Q1 Earnings Expected to Decline
by Zacks Equity Research
Organon (OGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Organon (OGN) Surpasses Market Returns: Some Facts Worth Knowing
by Zacks Equity Research
Organon (OGN) reachead $18.71 at the closing of the latest trading day, reflecting a +1.03% change compared to its last close.
Organon (OGN) Beats Stock Market Upswing: What Investors Need to Know
by Zacks Equity Research
In the closing of the recent trading day, Organon (OGN) stood at $18, denoting a +1.01% change from the preceding trading day.
Should WisdomTree U.S. SmallCap Dividend ETF (DES) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for DES
Organon (OGN) Advances While Market Declines: Some Information for Investors
by Zacks Equity Research
In the latest trading session, Organon (OGN) closed at $17.71, marking a +1.49% move from the previous day.
Molina (MOH) Wins Deal to Serve Michigan's Medicaid Members
by Zacks Equity Research
Molina Healthcare (MOH) wins a Medicaid contract from the MDHHS to better care for the healthcare needs of Michigan's Medicaid beneficiaries and therefore, gain more customers.
Play Safe! S&P 500 is Teasingly Close to its 50 DMA: 3 Picks
by Tirthankar Chakraborty
With the S&P 500 trading close to its 50-day moving average, it's wise for investors to place bets on safe stocks such as Iron Mountain (IRM), Organon (OGN), and International Business Machines (IBM).
Why HCA Healthcare (HCA) is a Smart Addition to Your Portfolio
by Zacks Equity Research
HCA Healthcare (HCA) remains well-poised for growth on growing patient volumes, buyouts, effective telehealth services and a notable financial stand.
Why the Market Dipped But Organon (OGN) Gained Today
by Zacks Equity Research
In the most recent trading session, Organon (OGN) closed at $18.16, indicating a +1.68% shift from the previous trading day.
Encompass Health (EHC) Plans a 50-Bed Facility to Serve Texas
by Zacks Equity Research
Encompass Health (EHC) unveils plans to build an inpatient rehabilitation hospital in San Antonio to bring improved health outcomes and further fortify its presence in Texas.
UnitedHealth (UNH) to Roll Out Medical Claims Software Soon
by Zacks Equity Research
UnitedHealth (UNH) assists care providers with more than $2 billion through several initiatives to mitigate the cash flow crunch arising from the cyberattack.
Here's Why You Should Retain Centene (CNC) Stock for Now
by Zacks Equity Research
Robust growth outlook, contract wins, accretive acquisitions and streamlining of businesses poise Centene (CNC) well for growth.
Markets Dip but it's Time to Buy These Low-Risk High-Income Stocks
by Shaun Pruitt
Now may be an ideal time to buy these lower-risk, high-income stocks especially as markets start to digest hot inflationary data.
Centene (CNC), Pearl Health Unite to Enhance Value-Based Care
by Zacks Equity Research
Centene (CNC) collaborates with Pearl Health to enhance value-based care services for Medicare Advantage members.
Here's Why You Should Add Cigna (CI) Stock to Your Portfolio
by Zacks Equity Research
Cigna's (CI) strong Evernorth and Cigna Healthcare segments, value enhancing initiatives and a positive 2024 outlook poise it well for growth.